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Abstract
Background: Acacia ataxacantha (Fabaceae), used in traditional medicine grows in the South-West of Bénin. Ethyl
acetate extract of the barks of this species was previously reported to display various bioactivities, including
antibacterial, antifungal and antioxidant activities. In the present study, we investigate the antimicrobial and
antioxidant activities of compound isolated from ethyl acetate extract of Acacia ataxacantha.
Methods: Purification, isolation and structural identification of isolated compound were done using various
chromatographic and spectroscopic methods. Antimicrobial activity was investigated using a two-fold serial
microdilution method. The inhibitory potency of isolated compound was evaluated by kinetic experiments. The
antioxidant activity was also determined using 2, 2-diphenyl-1-picrylhydrazyl.
Results: The isolated compound was identified as 7-hydroxy-2-methyl-6-[β-galactopyranosyl-propyl]-4H-chromen-4-
one. As far as we know, this compound, named “acthaside”, reported for the first time, was active against all tested
microorganisms with minimal inhibitory concentration ranging from 25 to 50 μg/ml. At 50 μl/ml, no growth was
observed in almost all tested microbial after 24 h of exposure. The isolated compound had significant antioxidant
activity with an IC50 value of 3.61 ± 0.12 μg/ml compared to quercetin (IC50 1.04 ± 0.01 μg/ml).
Conclusion: The present work demonstrates that the new chromen derivative isolated from A. ataxacantha may
help treat bacterial and yeast infections. However, further studies are required to clarify the mechanism of action of
this compound.
Keywords: Acacia ataxacantha, 7-hydroxy-2-methyl-6-[β-galactopyranosyl-propyl]-4H-Chromen-4-one (acthaside),
Antimicrobial, Antioxidant
Background
Infectious diseases are the main cause of approximately
one-half of all death in tropical countries. Some bacteria
and fungi extremely pathogenic, are principal causes of
these human infections. For several decades until now,
the antibiotherapy has been one of the most important
therapies used for fighting infectious diseases and has
tremendously enhanced the health aspects of human life
since its introduction. The discovery of antibiotics to
combat these pathogens marked a revolution in the
twentieth century [1]. However, the bacterial resistance
is spreading throughout the world, inducing a steadily
decreasing of relevant antibiotics [2]. The emergence of
microbial resistance and the decrease in effectiveness of
currently available antimicrobial agents requires the dis-
covery for new antimicrobial substances with novel in-
hibitory mechanisms. Medicinal plants represent an
alternative source for new antimicrobial agent discovery
[3]. Medicinal plants have been used for centuries to
treat infectious diseases and are considered as an obvi-
ous source of new antimicrobial compounds [4]. Num-
bers of bioactive metabolites have been isolated from
these natural sources. According to the World Health
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Organization (WHO), medicinal plants could be the
source of a variety of drugs. Antimicrobial properties of
medicinal plant are being increasingly reported from dif-
ferent parts of the world [5]. The uneven availability,
chemical diversity, structural complexity, lack of sub-
stantial toxic effects, and broad spectrum of antimicro-
bial activity of natural products, either as pure
compounds or as standardized plant extracts, provide
unlimited possibilities for new effective drugs and make
them ideal candidates for new therapeutics [6, 7]. Mem-
bers of the genus Acacia, which are widely distributed in
tropical and subtropical regions, consist of about 1200
species [8], and are used medicinally for several purposes
[9–12]. Previous phytochemical investigation on some
species of the genus Acacia led to the isolation of flavo-
noids [13, 14], terpenoids [15] and polyphenols [16]. To
the best of our knowledge, no phytochemical work has
yet been done on A. ataxacantha. This species is wide-
spread in much of sub-Saharan Africa. This species has
been reported in Benin, Nigeria and Kenya for the treat-
ment of tooth decay, dysentery, bronchitis, cough and
joint pain [17–19]. Antimicrobial and antioxidant activ-
ities of the extracts of A. ataxacantha have also been re-
ported previously [20, 21]. The lack of toxicity of the
bark of this species was also reported [22]. These results
suggest that this plant might contain bioactive com-
pounds that act as antimicrobial and antioxidant agents.
The present study were undertaken to evaluate anti-
microbial and antioxidant properties of a new chromen
derivative isolated from A. ataxacantha.
Methods
General experimental procedures
1D and 2D NMR spectra were recorded using
Bruker 400 MHz spectrometer. The chemical shifts
(δ) are reported in parts per million (ppm) relative
to tetramethylsilane (TMS δ = 0). The coupling
constants (J) are given in Hz. Deuterated methanol
(CD3OD) was used as solvent in the NMR experi-
ments. Mass spectral data ESI-MS, were recorded on
Agilent technology instrument Accurate Mass Q-ToF
spectrometer. The material used for chromatographic
separation was Sephadex LH-20. Pre-coated silica gel
60 F254 TLC plates (Merck, Germany) were used for
monitoring fractions and spots were detected with
UV light (254 and 365 nm). Mueller Hinton (Agar
and Broth) and Sabouraud Dextrose (Agar and
Broth) were used for preparation of culture media
for the antibacterial and antifungal activities
respectively. Gentamicin, 2,2-diphenyl-1-picrylhydra-
zyl (DPPH) radical, and quercetin were purchased
from Sigma-Aldrich Co., USA. All solvents used
were of analytical grade.
Collection and preparation of plant material
Fresh barks of Acacia ataxacantha were collected in
September 2012 from Ouidah, Department of Atlantic,
South of République du Bénin. Botanical identification
was performed by a botanist from the Herbier National
du Bénin at University of Abomey-Calavi and a speci-
men with voucher number AA 6509/HNB was deposited
at the same Herbarium. The collected plant material was
chopped into small pieces and air-dried in the laboratory
(22 °C), under shade for two weeks. The dry plant ma-
terial obtained was ground to a fine powder using an
electric grinder (Excella mixer grinder).
Preparation of plant extract
Dry powdered barks of A. ataxacantha (250 g) were suc-
cessively extracted with hexanes (3 × 500 ml), dichloro-
methane (3 × 500 ml), ethyl acetate (3 × 500 ml) and
methanol (3 × 500 ml) by maceration with continuous
shaking (at 24 °C for 72 h) using an orbital shaker (Ika
Ks 260 basic). The extracted matter from each solvent
was filtered first using a cotton plug followed by What-
man No 1 filter paper. The resulting extracts were con-
centrated using rotary evaporator (BUCHI Rotavapor
RII, Switzerland) under reduced pressure and extracts
were stored in refrigerator at 4 °C.
Isolation of bioactive compound
The best solvent system for column chromatography
was selected for elution after carrying out the TLC of
the ethyl acetate extract by the combinations of different
solvents such as dichloromethane, ethyl acetate and
methanol alternatively. Among all combination of sol-
vents, dichloromethane: methanol combination showed
the best resolution of the components of the extract on
TLC plate.
The ethyl acetate extract (1 g) was dissolved in 1 ml of
a mixture of CH2Cl2/CH3OH (50:50, v/v) and fraction-
ated using Sephadex LH-20 column (diameter: 4 cm;
Sephadex height: 25 cm). The elution solvent was the
mixture CH2Cl2/CH3OH (50:50 and 20:80 v/v), to afford
a total number of 31 fractions. A monitoring with TLC
of these fractions yielded four main fractions (I-IV).
Fraction III that consisted of major compounds in the
extract was subjected to further purification. Purification
of this fraction was done using preparative liquid chro-
matography (Gilson VP 250/21, Nucleodur 100-5 C18ec,
Macherey-Nagel, UV detection 220 and 254 nm) by gra-
dient elution (flow rate 20 ml/min) using water/aceto-
nitrile (85:15 to 00:100 v/v) with 0.1% trifluoroacetic
acid as mobile phase, to obtain compound 1 (9 mg).
Structural elucidation of isolated compound
Structural determination of the isolated compound was
carried out by spectrophotometric methods (1D and 2D
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NMR, mass and UV spectrometry). 1D and 2D NMR
spectrum were recorded at room temperature with a
Bruker NMR spectrometer 400 and 500 MHz in
CD3OD. The 2D experiments (COSY, NOESY, HSQC,
HMBC) were performed using standard Bruker
programs.
Acid hydrolysis of isolated compound
The isolated compound (1 mg) was dissolved in 6% HCl
(1 ml) and heat at 80 °C for 2 h. The mixture was then
extracted with CHCl3 (3 × 5 ml). The H2O phase was
evaporated and dried to obtain the monosaccharide resi-
due. This residue was identified as galactose by compari-
son with standards (galactose and glucose) on TLC in
CHCl3/CH3OH/H20 (8:5:1) [23].
Microbial strains
The microorganisms used in this study included Gram-
positives bacteria such as Staphylococcus aureus (ATCC
6538), Staphylococcus epidermidis (CIP8039), Entero-
coccus faecalis (ATCC 29212), Staphylococcus aureus
Methicillin Resistant (SAMR) and Gram-negative
Pseudomonas aeruginosa (CIP 82118). The microorgan-
isms were obtained from Laboratoire de Biophotonique
et Pharmacologie, University of Strasbourg, France. Can-
dida albicans (CIP 4872) strain was obtained from na-
tional laboratory of drug control in Cotonou (Bénin).
Bacterial cultures were maintained on Mueller-Hinton
agar (MHA) and yeast cultures were maintained in
Sabouraud Dextrose Agar (SDA) at 4 °C. Sub-culturing
was done weekly. The bacteria were inoculated in
Mueller-Hinton broth (MHB) for 18 h at 37 °C and yeast
in Sabouraud Dextrose broth (SDB) for 48 h at 30 °C,
prior to the test.
Minimum inhibitory concentration
The two-fold serial microdilution method was used to
determine the minimum inhibitory concentration (MIC)
values of isolated compound against microorganisms
[21]. The stock solution (1 mg/ml) was prepared by
solubilizing 1 mg of isolated compound in 50 μl of di-
methyl sulfoxide (DMSO 2.5%) followed by 950 μl of
MHB. Briefly, 100 μl of isolated compound (100 μg/ml),
gentamicin and fluconazole (50 μg/ml) were two-fold
serially diluted with Mueller-Hinton broth for antibac-
terial assay and Sabouraud broth for yeast assay in 96-
well microplates to make eight concentrations of isolated
compound (100-0.78 μg/ml) and control (50-0.39 μg/
ml). 100 μl of freshly culture of bacteria (106 CFU/ml)
and yeast (2 × 105 CFU/ml) was added to each well.
DMSO (2.5%) was used as negative control while genta-
micin and fluconazole were used as positive controls.
The microplates were covered and incubated at 37 °C.
After 18 h of incubation, 40 μl of 0.2 mg/ml solution of
p-iodonitrotetrazolium (INT) which is an indicator
solution for determination of bacterial growth were
added to each well and microplates were further incu-
bated at 37 °C. The minimal inhibitory concentration
was determined 30 min after addition of INT.
Minimum bactericidal and fungicidal concentration
The minimum bactericidal concentration (MBC) and
minimum fungicidal concentration (MFC) of isolated
compound was determined according to the method of
Escalona-Arranz et al. [24]. To determine the MBC and
MFC, aliquots of 20 μl from all dilutions not showing
any growth of bacteria and yeast were inoculated on
sterile MHA plates (for bacteria) and SDA (for yeast) by
spreading using swab sticks. Inoculated plates were incu-
bated at 37 °C for 24 h for all bacteria while those inocu-
lated with fungi were incubated at 30 °C for 48 h. After
incubation, the concentration at which there is no visible
growth of the organisms on the agar plates was recorded
as the minimal bactericidal concentration (MBC) for
bacteria and minimal fungicidal concentration (MFC)
for yeast. The experiment was carried out in triplicate.
Determination of MIC index
The MIC index (MBC/MIC) was calculated for isolated
compounds and positive controls to determine whether
a compound had bactericidal/fungicidal (MBC/MIC ≤4)
or bacteriostatic/fungistatic (4 < MBC/MIC <32) effect
on the growth of bacteria or fungi [25].
Time-kill kinetic index
The time-kill kinetic index of isolated compound was
determined as described by Miyasaki et al. [26] with
slight modifications. The objective of this test is to know
the duration of bactericidal or fungicidal effect of iso-
lated molecule. Briefly, bacterial and yeast overnight cul-
tures were diluted to the 106 CFU/mL with MH and SD
broth respectively. Equal volume of each diluted inocu-
lum and tested compound were mixed at their respective
predetermined MBC and MFC values and incubated
with shaking at respective temperature of 37 °C for bac-
teria and 30 °C for yeast. At different time intervals viz.
0, 1, 4, 8, 12, … 36 h, 0.1 mL of the mixed suspension
was spread on suitable agar petri dishes in triplicate and
incubated for 36 h at suitable temperature. After 18 h
incubation, viable colonies were enumerated. The results
were recorded in terms of log10 CFU and plotted vs.
time for each microbial tested.
In vitro antioxidant activity
The antioxidant activity of isolated compound on the
stable radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) was
performed using the method developed by Danielle and
Lall, [27] with slight modifications. In this assay, 96 wells
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plates were used. For this assay, the stock solution was
prepared by disolving 2 mg of isolated compound in
1 ml of methanol HPLC-grade to obtained 100 μg/ml.
Quercetin was also prepared at the same concentration
as the standard reference. Briefly, 200 μl of stock solu-
tion and quercetin was added separately to the wells in
the top row. This was followed by the addition of 100 μl
of methanol to the remaining wells. From the wells of
the first row of the plate, the two-fold serially dilutions
were performed to obtain a concentration ranges from
1.56 to 100 μg/ml. Finaly, 200 μl of methanolic solution
of 2,2-diphenyl-1-picrylhydrazyl (2%) were introduced in
each well of a microplate. The plates were allowed to de-
velop in the dark room for 30 min before the measure-
ment of the absorbance at 517 nm using a Microplate
Reader (Rayto-6500). The capability of the compound
and the reference standard to scavenging the free radical
was determined following formula bellow:





Where, ABlank is the absorbance of the control reaction
(containing all reagents except the test sample) and
Asample is the absorbance of sample (isolated compound
or quercetin).
The concentration of samples reducing 50% of free
radical DPPH (IC50) was determined using the regres-
sion line representing the inhibition percentage of DPPH
versus the sample concentration. The assay was repli-
cated three times and results are expressed as mean ±
standard deviation.
Statistical analysis
The results were expressed as means of triplicate deter-
mination ± standard deviation (SD). The graphical was
performed using the Graph Pad Prism 6.1 software
(Microsoft, USA).
Results and discussion
In our previous work, the ethyl acetate extract of bark of
Acacia ataxacantha was found to have significant activ-
ity against S. aureus (ATCC 6538), S. epidermidis (CIP
8039), E. faecalis (ATCC 29212), S. aureus Methicillin
Resistant (SARM) and P. aeruginosa (CIP 82118). Ethyl
acetate extract was active against all bacteria with the
minimum inhibitory concentrations values of 325 μg/ml
against S. aureus and 625 μg/ml against all other tested
bacteria [20]. The phytochemical analysis of this active
extract led to the isolation of a chromen derivative. The
structural identification of isolated compound was eluci-
dated using a combination of spectroscopic methods.
Biological activity of this compound was also evaluated.
Structural elucidation of isolated compound
The compound was isolated as white amorphous powder
which showed a violet-blue fluorescence in UV-365 nm
with KOH reagent on thin layer chromatogram. The
Mass spectra measured with LC-ESI-MS positive mode
showed a molecular ion at m/z 396.14203 [M + H]+
(calcd for C19H24O9, 396.14243). Its also showed UV
(CH3OH) λmax 225, 245 and 288 nm. The
1H and 13C
NMR spectra (Table 1) of isolated compound included
resonances corresponding to aromatic and glycosidic
protons and carbons (Table 1). The 1H NMR spectrum
of the compound in CD3OD showed two methyl at δH
2.25 (3H, d, J = 0.7 Hz) and 1.09 (3H, dt, J = 6.2,
3.6 Hz), two oxymethylene protons at δH 2.97 (1H, dd, J
= 12.1, 7.4Hz) and δH 3.68 (1H, dd, J = 12.1, 5.3Hz) and
one anomeric proton at δH 4.45 (1H, d, J = 7.8 Hz) cor-
related in the HSQC spectrum with one anomeric car-
bon at δC 103.0 in the
13C NMR spectrum. The 13C
NMR spectrum of isolated compound showed 19 carbon
signals, of which six were assigned to the sugar moieties
and the remaining 13 to the aglycone. The COSY and
1H spectra of isolated compound also showed two aro-
matic protons at δH 6.65 and 6.62 (each 1H, d, J =
2.4 Hz) assignable to H-6 and H-8 respectively (Fig. 1).
The HSQC spectrum allowed to correlate these protons
Table 1 NMR Spectroscopic data for acthaside
Position Isolated compound (acthaside)
δH (J in Hz) δC, type
1 - -
2 - 166.7, C
3 5.94, (d, 0.7) 111.6, CH
4 - 181.7, C
4a - 115.3, C
5 - 144.0, C
6 6.65 (d, 2.4) 119.8, CH
7 - 161.8, C
8 6.62 (d, 2.4) 102.6, CH
8a - 163.1, C
9 2.97 (dd, 12.1, 7.4)
3.68 (dd, 12.1, 5.3)
43.3, CH2
10 4.06 (m) 76.9, CH
11 1.09 (d, 6.2) 21.5, CH3
12 2.25 (d, 0.7) 19.9, CH3
1′ 4.45 (d, 8.0) 103.0, CH
2′ 3.07 (dd, 8.7, 8.0) 75.5, CH
3′ 3.27 (m) 78.3, CH
4′ 3.20 (m) 71.9, CH
5′ 3.21 (m) 77.9, CH
6′ 3.58 (m)
3.75 (dd, 11.8, 1.6)
62.9, CH2
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to carbons signal at δC 119.8 (C-6) and δC 102.6 (C-8).
Complete assignment of the remaining resonances of
the aglycone in the 13C NMR spectrum was achieved
by analysis of the HSQC and HMBC data, which con-
firmed the presence of 7-hydroxy-2-methyl-6-propyl-
4H-Chromen-4-one. Furthermore, one anomeric pro-
ton resonance corresponding to O-linked sugar was
displayed in the 1H NMR spectrum as one doublet at
δH 4.45 (J = 7.8 Hz) which correlate in HSQC to an
anomeric carbon at δC-1 103.0. Acid hydrolysis of iso-
lated compound led to identified galactose, by HPLC
comparison with a standard. The NOESY spectrum
showed NOE correlations between H-1′ and H-10, H2-9.
These results led to identify a β-D-galactopyranose as
described previously [28, 29]. A correlation between
H-1′-gal and δC 76.9 in the HMBC spectrum of iso-
lated compound specifies C-10 of the aglycone as the
site of O-glycosylation (Fig. 2). Thus, the structure of
isolated compound was elucidated as 7-hydroxy-2-methyl-
6-[β-galactopyranosyl-propyl]-4H-Chromen-4-one (Fig. 3).
As far as we know, this compound is a chromen derivative
which has not been reported previously (Additional file 1).
Antimicrobial activity of isolated compound
The isolated compound was evaluated in vitro for its
antimicrobial activity and the results are presented in
Table 2. Compound was tested for antimicrobial activity
by determining MIC, MBC and MFC against four
Gram-positive bacteria: Staphylococcus aureus ATCC
6538, Staphylococcus epidermidis CIP 8039, Enterococcus
faecalis ATCC 29212, Staphylococcus aureus Methicillin
Resistant, one Gram-negative bacteria: Pseudomonas
aeruginosa CIP 82118 and a fungi: Candida albicans
CIP 4872. The tested compound exhibited various
degrees of antimicrobial effect against the tested micro-
organisms. Many reports consider the antimicrobial
Fig. 1 1H-1H COSY correlations of isolated compound
Fig. 2 HMBC correlation of isolated compound
Fig. 3 Structure of 7-hydroxy-2-methyl-6-[-galactopyranosyl-propyl]-
4H-Chromen-4-one (acthaside), a new chromen derivative from the
bark of Acacia ataxacantha
Table 2 Minimum inhibitory concentration (MIC) and Minimum
bactericidal and fungicidal concentrations (MBC, MFC) of
acthaside (μg/ml) from A. ataxacantha against microorganisms
Minimum inhibitory concentrations (μg/ml)
Microorganismsa Gram (+) bacteria Gram (-) bacteria Yeast
S.a S.a.m.r S. ep E.f P.a C. a
Isolated compoundb 50 50 25 50 50 25
Gentamicin 0.39 0.39 0.78 0.39 0.78 Nt
Fluconazole Nt Nt Nt Nt Nt 0.78
Minimum bactericidal and fungicidal (μg/ml)
Isolated compoundb 50 50 25 50 50 25
Gentamicin 0.78 1.56 1.56 0.78 1.56 Nt
Fluconazole Nt Nt Nt Nt Nt 1.56
MIC index
Isolated compound 1 1 1 1 1 1
Gentamicin 2 4 2 2 2 Nt
Fluconazole Nt Nt Nt Nt Nt 2
a S. a : Staphylococcus aureus; S.a.m.r : Staphylococcus aureus methicillin
resitant; S.ep : Staphylococcus epidermidis; E. f: Enterococcus faecalis;
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activities to be significant if the MIC is ≤ 10 μg/ml,
moderate if 10 < MIC ≤ 100 μg/ml and low if MIC >
100 μg/ml [30, 31]. The tested compound had moderate
antibacterial activity against five test bacteria with MIC
and MBC ranging from 25 to 50 μg/ml. The isolated
compound had also moderate antifungal activity against
C. albicans with MIC and MFC values of 25 and 50 μg/
ml. Staphylococcus epidermidis and C. albicans were the
most sensitive with the MIC value of 25 μg/ml. The
mechanism of antibiosis of the isolated compound was
calculated using MIC index to elucidate whether the ob-
served antibacterial effects were bactericidal or bacterio-
static [25]. The isolated compound showed the same
values of MIC and MBC against S. aureus, MRSA, S. epi-
dermidis, E. faecalis and P. aeruginosa. The same values
obtained for MIC and MBC indicate the bactericidal
nature of isolated compound against these bacteria. The
isolated compound also showed a fungicidal effect
against Candida albicans (MIC = MFC). For decades
ago, the search for antimicrobials was oriented towards
the discovery of natural compounds that can inhibit
Gram-positive and gram-negative, which are most often
responsible for infectious diseases. Gram-positive
bacteria cause a broad spectrum of disease in immuno-
competent and immunocompromised hosts. Despite
increasing knowledge about resistance transmission
patterns and new antibiotics, these organisms continue
to cause significant morbidity and mortality, especially
in the health care setting [32]. The Gram-negative cell
wall (made up of lipopolysaccharide) is complex and
multilayered structure, which makes access to mem-
brane more restricted and barrier to many environmen-
tal substances including synthetic and natural antibiotics
[33]. The results of this study indicate that the acthaside,
isolated from A. ataxacantha, could be an agent able to
cross this tough barrier. Our results have also shown
that the tested compound was active against C. albicans,
suggesting its possible use in the treatment of fungal
infections.
Time-kill kinetic study
Previous researchers have used MICs and MBC as
prediction tools for antimicrobial action of plant extracts
or pure compounds, thus limiting the use of such data
since it does not consider time-related antimicrobial
effects, such as killing rate [34]. The kill kinetics
provides more accurate description of antimicrobial
agents than does the MIC [35]. In this study, we
explored the time-kill activity of acthaside isolated from
the barks of A. ataxacantha against S. aureus, SAMR, S.
epidermidis, E. faecalis, P. aeruginosa and C. albicans.
The rate of microbial killing after exposure to the MBC
or MFC of isolated compound was summarized in Fig. 4.
The time required to achieve a reduction of 3log10 CFU
is an acceptable index of bactericidal or fungicidal activ-
ity of analyzing time-kill [36]. The results showed that
no tested organisms showed significant bactericidal or
fungicidal activity in the first hour. However, 3log10
reduction in viability of all tested microorganism was
observed after 16 h of exposure. More interesting, the
3log10 CFU of C. albicans and S. epidermidis was
reduced to zero after 16 h exposure. The 3log10 CFU of
all others tested bacterial was reduced to zero after 20 h
of exposure except E. faecalis (24 h). According to some
authors, an antimicrobial agent is a “substance that kills
or inhibits the development and the multiplication of
microorganisms, such as bacteria, fungi, protozoa or
viruses” [37, 38]. Among numerous pure compounds
having this feature, acthaside could be considered. This
antimicrobial power of acthaside, could be due to the
presence of benzopyran ring (chromen) in its structure.
Chromens represent a class of secondary metabolites
that have generated great attention because of their
interesting biological and pharmacological properties
[39]. In additional, the new chromen derivative isolated
from A. ataxacantha shows broad spectrum of
antimicrobial activity against Gram-positive and Gram-
negative bacteria and yeast (C.albicans). These results
corroborate with the work of Charles et al. [40] which
showed that uvafzelin (a chromen derivative), isolated
from the stems of Uvaria ufielii has presented a broad
spectrum of antimicrobial activity against Gram-positive
and acid-fast bacteria. A key feature is that the lipophilic
nature of the chromen derivatives helps to cross the cell
membrane easily [41].
Antioxidant activity
The hydrogen-donating activity measured using DPPH
radicals as hydrogen acceptor, showed dose-dependent
activity. The results were compared to quercetin (Fig. 5).
From 1.56 to 12.5 μg/ml the scavenging activity of
Fig. 4 Time-Kill kinetic analysis of acthaside against tested baterial
and yeast
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isolated compound varied from 34.03 to 51.32% com-
pared to the control (42 .71 to 84.93%). From 25 to
100 μg/ml, the percentage of inhibition of DPPH radical
varied from 53.67 to 73.12% for isolated compound and
from 85.94 to 86.28% for the control (quercetin). The
concentration of antioxidant required for 50% scaven-
ging (IC50) of DPPH radicals was also determined. The
IC50 value, is a parameter widely used to measure anti-
oxidant activity. The new chromene derivative isolated
from A. ataxacantha had interesting antioxidant activity
with an IC50 of 3.61 ± 0.12 μg/ml compared to quercetin
(IC50 1.04 ± 0.01 μg/ml). The antioxidant activity of this
compound could be assigned to its phenolic nature. The
presence of electron-donating substituents such as -OH,
on the chromen core could also be responsible of inter-
sting radical scavenging activity. Thus, this compound
would reduce free radicals and then prevent cell damage.
The antioxidant power of this new compound would
justify its antimicrobial broad-spectrum activity against
Gram-positive and Gram-negative bacteria and against
yeast (C. albicans). It has been demonstrated, an
increase in the antimicrobial activity of pure compounds
when they are combined with antioxidants [42]. There-
fore, we consider that if a compound has antimicrobial
and antioxidant properties, this dual effect could en-
hance its antimicrobial activity.
Conclusion
The present research work through a systematic chem-
ical and biological investigation has determined and
identified for the first time the compound 7-hydroxy-2-
methyl-6-[β-galacto-propyl]-4H-chromen-4-one (actha-
side) as a new antimicrobial substance and antioxidant,
isolated from A. ataxacantha. This study demonstrated
that the isolated compound present a broad spectrum
antimicrobial activities against Gram-positive and Gram-
negative bacteria and also against C. albicans (yeast).
The isolated compound has also showed a promising
antioxidant activity when compared with standard drugs.
The results obtained in the present study showed the
interest of the ethnopharmacological and chemotaxo-
nomic approaches in the search for active substances
against the microbial infections. The active tested com-
pound may, either to be a model for the synthesis of
more active and less toxic analogues or to be used in
association with antimicrobial commercial drug, as they
may reverse the resistance of microbial to antimicrobial
drugs. However whether the new compound isolated
should act as an effective therapeutic agent, the study of
its mechanism of action would be necessary before
application.
Additional file
Additional file 1: NMR and MS spectrum of the new chromone
derivative (Acthaside). (PDF 439 kb)
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